Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service incontinence, prolapse & sacral neuromodulation cases in Tennessee: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (219 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 34 | 2,804 | 43% |
| 2020 | 36 | 2,459 | 46% |
| 2021 | 39 |
Slings, artificial sphincter, colpopexy, sacral neuromodulation, penile prosthesis. Professional codes (what the surgeon bills): CPT 57288, 53440, 53445, 57425, 57282, 57283, 64581, 64590, 54405.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 51% of the cases CMS names in Tennessee; 26 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 110 | 4,594−3.3%/yr | −3.3%/yr | 6.61.3× | 25% | 4,840 in 2030+0.9%/yr |
| BPH procedures |
Incontinence, prolapse & sacral neuromodulation in every state, and its device makers · Every procedure market in Tennessee · Every state · Compare with Florida
| 2024 |
| 2,360 |
| 57% |
| 2025 est. | ≈ 2,520 | – |
| 2026 est. | ≈ 2,550 | – |
| 2,748 |
| 49% |
| 2022 | 39 | 2,626 | 52% |
| 2023 | 44 | 2,507 | 55% |
| 2024 | 43 | 2,360 | 57% |
| 2025 from claims | – | 2,522 2,314–2,668 | 57% |
| 2026 forecast | – | 2,549 2,243–2,941 | 58% |
| 2027 forecast | – | 2,574 2,201–3,067 | 58% |
| 2028 forecast | – | 2,599 2,169–3,183 | 58% |
| 2029 forecast | – | 2,624 2,143–3,291 | 59% |
| 2030 forecast | – | 2,649 2,122–3,395 | 59% |
In 2025, 74% hospital outpatient, 26% surgery center. The share outside the hospital has moved +10 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| 6,023−0.4%/yr |
| −0.4%/yr |
| 2.8 |
| 24% |
| 8,340 in 2030+5.6%/yr |
| Georgia | 34 | 2,423−0.2%/yr | −0.2%/yr | 2.8 | 14% | 2,640 in 2030+1.4%/yr |
| North Carolina | 32 | 2,349−2.5%/yr | −2.5%/yr | 2.4 | 5% | 2,230 in 2030−0.8%/yr |
| Virginia | 31 | 2,058−0.5%/yr | −0.5%/yr | 2.0 | 11% | 2,110 in 2030+0.4%/yr |
| South Carolina | 21 | 1,697−2.4%/yr | −2.4%/yr | 2.5 | 15% | 2,220 in 2030+4.6%/yr |
| Maryland | 35 | 1,684+0.8%/yr | +0.8%/yr | 1.9 | 34% | 1,910 in 2030+2.1%/yr |
| Oklahoma | 26 | 1,344−7%/yr | −7%/yr | 2.8 | 10% | 1,310 in 2030−0.5%/yr |
| Alabama | 17 | 1,302−0.1%/yr | −0.1%/yr | 2.9 | 16% | 1,480 in 2030+2.2%/yr |
| Arkansas | 21 | 1,234−4.1%/yr | −4.1%/yr | 3.2 | 30% | 1,060 in 2030−2.6%/yr |
| Kentucky | 10 | 902−8.4%/yr | −8.4%/yr | 2.0 | 11% | 950 in 2030+0.9%/yr |
| Mississippi | 14 | 901−6.8%/yr | −6.8%/yr | 2.4 | 45% | 1,040 in 2030+2.4%/yr |
| Louisiana | 10 | 866−4%/yr | −4%/yr | 2.1 | 3% | 710 in 2030−3.3%/yr |
| West Virginia | 6 | 311−5%/yr | −5%/yr | 1.5 | 0% | 360 in 2030+2.4%/yr |
| District of Columbia | 4 | 288+6.1%/yr | +6.1%/yr | 4.6 | 13% | 350 in 2030+3.4%/yr |
| Delaware | 3 | 284−1.8%/yr | −1.8%/yr | 1.6 | 0% | 370 in 2030+4.5%/yr |
| 62 |
| 4,487−4.2%/yr |
| −4.2%/yr |
| 6.31.3× |
| 43% |
| 4,180 in 2030−1.2%/yr |
| Hysterectomy, hysteroscopy & ablation | 25 | 1,879−1.2%/yr | −1.2%/yr | 2.91.1× | 11% | 1,860 in 2030−0.2%/yr |
| Prostatectomy & nephrectomy | 17 | 996−5.4%/yr | −5.4%/yr | 1.61.3× | 0% | 1,110 in 2030+1.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 87% of company spending on these surgeons in 2025, −4 pts on 2024.
In 2025, 9 companies reported engagement with Tennessee’s surgeons worth $575K in consulting, speaking, meals and travel tied to these products, about $13K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.